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Abstract
OBJECTIVE: To assess the efficacy and safety of Chi-
nese patent medicine (CPM) with the principle of
tonifying Qi, promoting blood circulation by remov-
ing blood stasis, and resolving phlegm (TQ-PBC-RP)
in the management of stable chronic obstructive
pulmonary disease (COPD).
METHODS: A systematic review of randomized
controlled trials (RCTs) identified from electronic
databases and print was conducted. RCTs testing
CPMs with TQ-PBC-RP against any type of con-
trolled intervention in patients with stable COPD
and assessing clinically relevant outcomes were in-
cluded. Methodological quality was evaluated with
the risk of bias tool according to systematic review
handbook 5.0.2. Quality of evidence was estimated
by the rating approach developed by the Grading
of Recommendations, Assessment, Development,
and EvaluationWorking Group.
RESULTS: Thirteen eligible RCTs with 12 oral CPMs
were tested. Significant differences between
groups in favor of CPMs were not reported in all tri-
als. Most trials included were deemed to be of low
methodological quality with poor evidence quality.
Because of large data heterogeneity, statistical
pooling was not performed for all outcomes.
CONCLUSION: The effectiveness of CPM in the
treatment of stable COPD is not supported by evi-
dence. Currently, evidence from RCTs is scarce and
methodologically weak. Considering the popularity
of CPMs among patients undergoing COPD, rigor-
ously designed trials are warranted.
© 2015 JTCM. All rights reserved.
Key words: Medicine, Chinese traditional; Pulmo-
nary disease, chronic obstructive; Randomized con-
trolled trial; Review; Reinforcing Qi-activating
blood; Blood-activating stasis-removing
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
major public health problem, and contributes to enor-
mous economic and social burdens.1,2 COPD was the
fourth-leading global cause of death in 19903 but rose
to the third by 2010.4 The burden on patients and soci-
ety imposed by COPD is more severe in China and
1
JTCM |www. journaltcm. com February 15, 2015 |Volume 35 | Issue 1 |
LiuW et al. / Systematic Review
other developing countries.5,6 Routine Western Medi-
cine (WM) for stable COPD mainly involves inhaled
bronchodilators and corticosteroids, which can im-
prove clinical symptoms, but fail to prevent the further
decline of lung function and repeated exacerbations.
Moreover, inevitable adverse events (AEs) and high
costs result in clinical limitations of WM. Therefore,
the number of stable COPD patients who fall back on
Traditional Chinese Medicine (TCM) as a complemen-
tary and alternative treatment is increasing steadily in
both China and some other Asian countries.7
In the thousands of years before the introduction of
WM to China, Chinese people relied on TCM for dis-
ease treatment. In modern society, TCM is indispens-
able for treating COPD, justified through positive evi-
dence from plentiful classic literature, case reports, and
clinical trials.8-11 In TCM theory, the fundamental path-
ological factors involved in stable COPD are theorized
to be Qi deficiency, blood stasis, and phlegm turbidity,
which can reciprocally result in COPD and mutually
infiltrate the lungs.12-14 Therefore, the principle of toni-
fying Qi, promoting blood circulation by removing
blood stasis, and resolving phlegm (TQ-PBC-RP) has
been developed to treat each pathogenic factor. Com-
pared with herbal decoctions, proprietary CPMs are
more convenient to eat and take along. Many studies
have shown promising effects of TQ-PBC-RP CPMs
on the improvement of clinical COPD symptoms and
quality of life, and reductions in exacerbations and
mortalities of COPD. In addition, these CPMs were
demonstrated to effectively prevent declining lung
function.15,16
Many systematic reviews have been conducted to assess
the efficacy and safety of TCM in the management of
stable COPD.17 However, no studies have examined
CPMs that treat based on specific principles. There-
fore, we aimed to assess the efficacy and safety of
TQ-PBC-RP CPMs in the treatment of stable COPD.
This review is expected to provide more evi-
dence-based information for the clinical use of CPMs.
MATERIALS ANDMETHODS
Search strategy
The following electronic databases were searched for ar-
ticles from their individual inceptions to December
31st, 2012: Chinese National Knowledge Infrastruc-
ture Database (CNKI), Wanfang Database, Excerpta
Medica Database (EMBASE), MEDLINE (PubMed),
China Science and Technology Journal Database
(VIP), China Biology Medicine disc (CBMdisc),
Google Scholar, and Cochrane Collaborative Library.
Search strategies were tailored respectively to comply
with each database, and no language restrictions were
applied. Search terms included: "chronic obstructive
pulmonary disease," "herbal medicine," "Chinese pat-
ent medicine," "Traditional Chinese Medicine," and
relevant derivatives were used individually or com-
bined. We also contacted authors and manufacturers
for more information including unpublished data.
Moreover, manual searching for bibliographies of all re-
trieved trials, relevant peer-reviewed journals, confer-
ence proceedings, and unpublished studies was con-
ducted.
Eligibility criteria
To be eligible for inclusion, a trial needed to: (a) in-
volve patients with COPD confirmed by post-broncho-
dilator spirometry of forced expiratory volume in 1 sec-
ond (FEV1) / forced vial capacity (FVC) ratio of < 70%
and a FEV1% of < 80%, in any age, gender, profession,
or ethnicity and without severe heart, renal, or hepatic
failure; (b) be randomized and controlled, regardless of
blinding; (c) include a head-to-head comparison of
TQ-PBC-RP CPM in oral administration, combined
or not combined with WM, vs WM alone, placebo, or
no treatment; (d) propose TQ-PBC-RP as prescription
principle of CPM used in the trial group and illustrate
every single herbal component; (e) report at least one
of the following outcomes: primary outcomes: spiro-
metric parameters; total effective rate, defined as a re-
duction rate of symptom scores (cough, cough-up
phlegm, dyspnea, wheezing, or other lung symp-
toms) ≥ 30% according to the Guiding Principle of
Clinical Research on New Drugs of TCM;18,19 second-
ary outcomes: quality of life (QoL) score; and adverse
events.
Study selection
Duplicate studies resulting from various databases were
removed by two reviewers (Song Yaling and Li Jian).
The other two reviewers (Liu Wei and Yang Shuang)
screened the titles and abstracts of all remaining cita-
tions independently to exclude articles that obviously
did not satisfy the inclusion criteria and then scruti-
nized the full text of any article that was deemed to be
potentially eligible. Finally, the selection results were
discussed together by the four reviewers. Any disagree-
ment about study eligibilities after discussion was re-
solved by consulting the fifth reviewer (MF).
Data extraction
Data concerning study design, participants, interven-
tions, follow-up, herbal composition, outcomes, and
AEs were extracted by two reviewers independently
(Liu Wei and Yang Shuang) and checked by a third par-
ty (MF). Missing information from one trial20 was re-
quested by contacting the original author by e-mail. To
date, no response has been received. Therefore, it was
not included.
Quality assessment
Two reviewers (LW and YS) evaluated the risk of bias
of included RCTs separately using a detailed list of
quality items recommended by the Cochrane Systemat-
ic Review Handbook 5.1.0.21 Information on method-
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ological quality was sought for the following seven do-
mains: randomization sequence generation; allocation
concealment; blinding of participants, experimenters,
and personnel; a statement on how dropouts and pa-
tients lost to follow-up were handled; selective report-
ing bias; other source of potential bias resulting from
the interest-related issues; and use of an inten-
tion-to-treat (ITT) analysis. The risk of bias for each
domain was summarized into three categories: a Yes for
low consideration of bias, a No for high risk of bias,
and an unclear for insufficient required information.
We also used the Grading of Recommendations, Assess-
ment, Development and Evaluation working group
(GRADE) profiler (The GRADE Working Group, ver-
sion 3.2, Geneva, Switzerland) to grade the quality of
evidence pertaining to individual outcomes across stud-
ies. We explored the factors that can reduce the quality
of evidence including limitations in study design (risk
of bias), inconsistency of results, indirectness of evi-
dence, imprecision, and publication bias. Discrepancies
about quality assessments were resolved by consensus
of the two reviewers (WL and SY) or consulting the
third party (MF).
Statistical analysis
Heterogeneity was assessed graphically using forest
plots, and statistically using the χ2 test. Data from indi-
vidual studies were pooled using a fixed-effects model
if no statistical heterogeneity (P < 0.05) was detected.
In cases of statistical heterogeneity, pooling data were
analyzed with a random-effects model. Subgroup analy-
sis was conducted if necessary. Descriptive analysis was
used if heterogeneity was too large. Dichotomous data
were presented as relative risks (RRs), and continuous
data as weighted mean differences (WMDs) or stan-
dardized mean differences (SMDs) with correspond-
ing 95% confidence intervals (CIs). Statistical analy-
ses were carried out using Review Manager 5.2 soft-
ware,22 developed by The Cochrane Collaboration
Group.
RESULTS
Searching process and description of the included
studies
The flow chart in Figure 1 depicts the process from
identification to final study inclusion. A total of 1442
Excluded after full-text rescreening (n = 428)
Redundant records (n = 8)
Review records; animal, tissue or cell experiments; theory
introduction (n = 2)
Non-RCT (n = 63)
Non-multitherapy principale of tonifying Qi, Promoting
Blood circulation by removing blood stasis and resolving the
phlegm (n = 212)
Non-oral Chinese patent drugs (n = 83)
Asthma or other pulmonary diseases (n = 4)
Case-control study (n = 9)
Intervention of control group is another kind of proprietary
Chinese medicine (n = 32)
Non-cocurrent RCT (n = 2)
Incomplete outcomes (n =12)
Patients in acute exacerbation stage (n = 1)
Initial number after searching (n = 1442)
Database searching (n = 1434) CNKI (n = 265)
Wanfang Database (n = 323)
EMBASE (n = 156) MEDLINE (n = 127)
VIP (n =82) CBMdisc (n = 401) Google Scholar (n = 42)
Cochrane Library (n = 38) Manual searching (n = 8)
Excluded after titles and abstracts screening (n = 1001)
Redundant records (n = 215)
Review records; animal, tissue/cell experiments; theory
introduction (n = 218)
Non-RCT (n = 22)
Non-multitherapy principle of TQ-PBC-RP (n = 31)
Non-oral Chinese patent drugs (n = 277)
Combined with other traditional extrapulmonary treatments
(n = 59)
Comorbidities of severe heart, renal or hepatic failure (n = 25)
Asthma or other pulmonary diseases (n = 105)
Case-control study (n = 2)
Interventions of control group are another kind of proprietary
Chinese medicine (n = 42)
Patients in acute exacerbation stage (n = 5)Potential eligible trials (n = 441)
Included trials (n = 13)
Figure 1 Study flow from identification to final inclusion of studies
CNKI: Chinese National Knowledge Infrastructure Database; EMBASE: Excerpta Medica Database; VIP: China Science and Technolo-
gy Journal Database; CBMdisc: China Biology Medicine disc; RCT: randomized controlled trial; TQ-PBC-RP: resolving phlegm.
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potentially relevant titles and abstracts were identified,
of which 1001 were excluded. The remaining 441 arti-
cles required us to retrieve the full text for further iden-
tification. Thirteen RCTs with sample sizes from
38-263 subjects fulfilled the eligibility criteria (Table 1).
One unpublished RCT was included.23 All included
studies were conducted in China and published in Chi-
nese between 1999 and 2012.
Study participants
A total of 1269 subjects were randomized and 1152
were analyzed by the original investigators. In 12
RCTs, patients were diagnosed as COPD according to
diagnosis criteria produced by the Chinese Society of
Respiratory Disease,36 and in one RCT24 patients were
diagnosed with chronic bronchitis (CB) according to
the National Clinical Professional Meeting on Chronic
Bronchitis.37 Table 1 lists the characteristics of partici-
pants in each identified study.
Study interventions
Twelve CPMs were used in the thirteen studies, of
which five were prepared in granules, four were in cap-
sules, one was in tablets, one was in syrup, and one was
an aqueous solution. Trials included were categorized
into four subgroups according to intervention style:
CPM vs placebo in six RCTs, CPM vs WM in three
RCTs, CPM vs no treatment in two RCTs, and adju-
vant use of CPM and WM (CPM&WM) vs WM in
two RCTs. Table 2 shows the characteristics of inter-
ventions for included RCTs.
Assessment of risk of bias
Each RCT indicated a randomization method. Howev-
er, only eight explained details of randomization se-
quence generation. Only two trials23,25 mentioned the
method of allocation concealment. Five RCTs used pla-
cebo-control and six RCTs mentioned blinding, but no
descriptions of blinding measures were mentioned.
Therefore, it could not be ascertained whether the
blinding was implemented adequately. Six RCTs men-
tioned patient dropouts, while only three detailed rea-
sons for dropout. Gao et al 24 reported four dropouts
because of symptom exacerbations. Zhang et al 29 listed
eight exclusions, of which seven subjects were eliminat-
ed because of poor compliance, while one subject was
eliminated because of misdiagnosis. Gong30 described
two dropouts because of contact lost. No sufficient in-
formation about data integrity in the other RCTs was
included. There were no preceding protocols for the eli-
gible trials included. Therefore, it was difficult to deter-
mine whether there was selective result reporting. We
were unable to determine whether the 13 RCTs had
other potential sources of bias. No trials included ITT
analysis (Table 3, Figure 2).
Assessment of evidence quality
Quality of evidence for individual outcome was mostly
graded as very low (Table 4).
Adverse events (AEs)
Either drug-related or all-cause adverse reactions were
collected. Only three trials reported AEs. All of these
AEs were mild and the incidence of AEs was low
(1.2%).
Measurement outcomes
All trials claimed positive effects of CPM for COPD
Study
Fu M 201223
Gao J et al 199924
Sun ZT et al 200925
Zhou WQ et al 200526
Wu L et al 201127
Zhong HW et al 201028
Zhang W et al 200829
Gong J 200730
Fang LP et al 200831
Hong ML et al 200532
Zhu LF 200933
Cai M 200534
Wang YF 200735
Setting
OP&IP
NR
OP
OP&IP
OP
OP&IP
OP&IP
OP&IP
NR
OP&IP
NR
OP&IP
NR
Number
(T/C)
130 (69/61)
61 (30/31)
60 (30/30)
136 (68/68)
263 (178/85)
87 (44/43)
62 (30/32)
56 (28/28)
56 (30/26)
38 (20/18)
64 (32/32)
80 (40/40)
60 (30/30)
Age (years)
(T/C)
60.8±8.2/60.5±11.0
≥60
61.0±9.0/59.5±10.9
70.3±5.0/69.0±6.4
68.9±8.8/68.4±8.8
64.1±10.8/65.1±9.8
63.1±5.7/65.9±5.6
58.5±5.9/57.4±8.0
68.0±5.7/68.0±5.0
67.7±5.7/66.9±5.6
63.7±7.5/62.9±8.3
<50, 3/5; 50-59, 12/11;
60-69, 18/17; >70, 7/7
45-78 (Mean: 62.8)/40-75
(Mean: 60.5)
Sex
(M/F)
80/50
NR
43/17
91/45
228/35
54/33
39/23
33/23
49/7
33/5
53/11
57/23
32/28
Disease course (years)
(T/C)
NR
NR
NR
17.4±2.1/18.3±6.1
NR
≥2
NR
13.9±2.5/14.0±2.3
NR
15.0±5.5/14.3±7.2
NR
4-30 (Mean: 16.5)/4-33
(Mean: 17.2)
4-25 (Mean: 25)/3-27
(Mean: 18)
Notes: T: the Trial group; C: the control group; NR: not reported; M: male; F: female; OP: outpatient; IP: inpatient.
Table 1 Characteristics of participants
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when analyzed by standard statistical techniques using
risk ratios or mean differences. Because of the great het-
erogeneity across studies, we performed a narrative syn-
thesis instead of pooled statistics. This analysis exclud-
ed two trials23,25 with favorable homogeneity, which had
the same CPM intervention in the trial group.
Four RCTs compared CPM with placebo for FEV1.
Two RCTs23,26 showed better effects on FEV1 improve-
ment in CPM group compared with the control, and
reported a significant difference between groups
[MD = 0.21, 95% CI (0.02, 0.40); MD = 0.29, 95%
CI (0.12, 0.46)]. Two other RCTs21,27 found the same
effect between groups. Two studies29,30 compared CPM
with WM, but no statistical difference was reported in
either trial. There were no statistically significant differ-
ences concluded by each trial.31,32 Two RCTs34,35 showed
better effects favoring the CPM&WM group com-
pared with WM [MD = 0.30, 95% CI (0.27, 0.33);
MD = 0.36, 95% CI (0.05, 0.67)].
Three RCTs23,25,27 compared CPM with placebo, and
one study25 showed better improvement of FEV1/FVC,
significantly favoring CPM [MD = 10.59, 95% CI
CaiM
2005 35
CaoJ1999 24
FangLP2008 32
FuM
2012 22
GongJ2007 31
HongML2005 33
SunZT2009 26
WangYF2007 36
WuL2011 28
ZhangW
2008 30
ZhangHW
2010 29
ZhouW
Q
2005 27
ZhuLF2009 34
Random sequence generation (selection bias)
Allocation concealmen (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Figure 2 Risk of bias summary
Study
Fu M 201223
Gao J et al 199924
Sun ZT et al
200925
Zhou WQ et al
200526
Wu L et al 201127
Zhong HW et al
201028
Zhang W et al
200829
Gong J 200730
Fang LP et al
200831
Hong ML et al
200532
Zhu LF et al
200933
Cai M et al
200534
Wang YF et al
200735
Randomization
description
Random
number table
Random
number table
Random
number table
Random
number table
NR
Coin flipping
NR
NR
NR
Random
number table
Random allo-
cation Software
NR
Random
number table
Allocation
concealment
Y
NR
Y
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
Blinding
DB
SB
DB
SB
DB
NR
NR
NR
NR
SB
NR
NR
NR
Integrity of
outcomes
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
Selective
reporting
bias
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
Other
bias
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
UN
Dropouts and
lost to follow-up
38
4
NR
NR
49
NR
8
4
14
NR
NR
NR
NR
ITT
Analysis
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
Table 3 Methodology characteristics of included RCTs
Notes: NR: not reported; Y: yes; DB: double-blind; SB: single-blind; UN: unclear; ITT: intention-to-treat analysis; RCTs: randomized
controlled trials.
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(5.14, 16.04)]. Two RCTs28,30 stud-
ied CPM vs WM. In the first
CPM vs WM study,28 there was a
significantly better effect on the
improvement of FEV1/FVC
[MD = 12.17, 95% CI (6.65,
17.69)]. However, the other study
did not show a significant differ-
ence between two groups.30 Two
RCTs33,35 compared CPM&WM
with WM. Only one trial33
showed effects that favored the
treatment group [MD = 7.16,
95% CI (1.05, 13.27)].
Global effective rate was studied
in eight RCTs. Two RCTs23,25
showed a higher total effective
rate of the same CPM compared
with placebo [pooled RR = 2.61,
95% CI (1.69, 4.05)]. Another
RCT27 also showed statistically sig-
nificant differences between two
groups [RR = 1.52, 95% CI
(1.21, 1.93)]. Two RCTs28,29 com-
pared CPM with WMs and
found a significant difference be-
tween the groups [RR = 1.31,
95% CI (1.04, 1.66); RR = 1.42,
95% CI (1.09, 1.85)]. One
study29 found that the CPM
group was not significantly differ-
ent from the control group. Two
RCTs33,34 studied CPM&WM vs
WM, and one33 demonstrated a
statistically significant difference
between the two groups [RR =
1.23, 95% CI (1.01, 1.51)].
QoL score was analyzed in five
RCTs. Four trials used St.
George's Respiratory Question-
naire and one trial32 used quality
of life assessing tables produced
by Cai et al.38 Two RCTs23,25 dem-
onstrated a better effect on the de-
creasing QoL score in the CPM
group compared with the placebo
[pooled SMD = ﹣0.62, 95% CI
(﹣0.91,﹣0.33)]. One RCT27 al-
so found a significant difference
between groups in favor of CPM
[SMD =﹣0.32, 95% CI (﹣0.61,
﹣ 0.03)]. One RCT32 compared
CPM with blank control and
found no difference between the
two groups. One RCT33 compared
CPM & WM with WM, and
found significant differences be-
tween the groups [SMD =﹣0.63,
95%CI (﹣1.14,﹣0.13)].Eff
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DISCUSSION
This systematic review, which included mostly
poor-quality RCTs, had some limitations. Although we
did not limit the publishing language, all studies were
written in Chinese and conducted in China. This
might result from searching strategy restrictions. There-
fore, a location bias should be considered. Additionally,
no multicenter trials were included. While all trials re-
ported baseline comparability, disease duration and
classification were not explained in all trials, which
could lead to a possible selection bias. No sample sizes
were estimated before the start of any trial. Further-
more, no information about concomitant treatments
was available in any RCT. Some trials used A+B vs B
design, which is likely to result in false positives.39
Twelve CPMs studied in this review used different
drug compositions, dosage, treatment duration, and
method of use. Therefore, pooled averages across stud-
ies could not be calculated. In seven studies, CPMs
were prepared in the pharmacy department of the par-
ticipating hospital. In three studies, CPMs were pro-
duced by pharmaceutical companies. However, it was
not clear whether these companies were sponsors, so
business interest-related possibilities could not be ex-
cluded. Furthermore, neither negative results nor re-
search protocols were provided. Therefore, selective re-
port bias and publication bias could not be ruled out.
Another important shortcoming of this review was in-
adequate description of randomization procedures. Al-
though all trials mentioned randomization, only seven
described the method of generation sequence, and allo-
cation concealment was only used in two of those sev-
en trials. Thus, it is doubtful whether effective random-
ization was used in the remaining five trials, which
may lead to selection and detection bias. Absence of
dropout reporting in seven trials made it uncertain
whether these trials had no dropouts or just a lack of re-
porting, which could contribute to attrition bias. None
of the trials included provided information on compli-
ance assurance measures for patients recruited. Some
studies gave no intervention to patients in the control
group, but provided no ethics approval. Overall, the
poor methodological quality of included RCTs leads to
low evidence quality. Therefore, conclusions from this
review should be treated with caution.
The CPM herbal prescriptions were designed to treat
three fundamental factors, namely Qi deficiency, blood
stasis, and phlegm turbidity. For example, Renshen (Ra-
dix Ginseng), Dangshen (Radix Codonopsis), and
Huangqi (Radix Astragali Mongolici) are often used as
Qi invigorators; Danggui (Radix Angelicae Sinensis),
Danshen (Radix Salviae Miltiorrhizae), and Chuanx-
iong (Rhizoma Chuanxiong) are often prescribed as
blood circulation activators; and Baibu (Radix Stemo-
nae), Banxia (Rhizoma Pinelliae), Ziwan (Radix Asteris
Tatarici), and Chuanbeimu (Bulbus Fritillariae Cirrho-
sae) are usually applied as expectorants.
With developing epidemiology, TCM researchers have
carried out many RCTs with CPM, and making objec-
tive evaluations of clinical effects is the priority. Some
propose that GRADE criteria should be introduced in
TCM clinical research with appropriate adjustment, ac-
cording to TCM characteristics.40 This review shows
preliminary evidence on the potential benefits of CPM
for stable COPD. However, the results should be inter-
preted with caution because of the limited study num-
ber and unsatisfying methodological quality. Rigorous-
ly designed RCTs are required to confirm the conclu-
sion of this review and facilitate internationality and
modernization of TCM.
ACKNOWLEDGMENTS
The authors would like to acknowledge Professor Wu
Taixiang, a leading member of the Chinese Evi-
dence-Based Medicine/Cochrane Center, West China
Hospital, Sichuan University, for his helpful advice on
quality evaluation.
REFERENCES
1 Global Initiative for Chronic Obstructive Lung Disease
(GOLD). Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease,
2011-12-30, cited 2012-02-14. Available from URL:http:
//www.goldcopd.org; 2011.
2 Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and
management of stable chronic obstructive pulmonary dis-
ease: a clinical practice guideline update from the Ameri-
can College of Physicians, American College of Chest Phy-
sicians, American Thoracic Society, and European Respira-
tory Society. Ann Intern Med 2011; 155(3): 179-191.
3 Mathers CD, Loncar D. Projections of global mortality
and burden of disease from 2002 to 2030. PLoS Med
2006; 3(11): e442.
4 Lozzano R, Naghavi M, Foreman K, et al. Global and re-
gional mortality from 235 causes of death for 20 age
groups in 1990 and 2010: a systematic analysis for the
global burden of disease study 2010. Lancet 2012; 380
(9859): 2095-2128.
5 Fang X, Wang X, Bai C. COPD in China: the burden
and importance of proper management. Chest 2011; 139
(4): 920-929.
6 Raherison C, Girodet PO. Epidemiology of COPD. Eur
Respir Rev 2009; 18(114): 213-221.
7 Sorkness RL. CAM and respiratory disease. Nutr Clin
Pract 2009; 24(5): 609-615.
8 Zhou W, Zhong YQ, Yang HM, et al. Traditional Chinese
Medicine in the treatment of chronic obstructive pulmo-
nary disease in stable stage: a systematic review of random-
ized controlled trials. Zhong Guo Xun Zheng Yi Xue Za
Zhi 2009; 9(3): 311-318.
9 Lu ZM, Chen SN. Advancements of TCM treatment in
chronic obstructive pulmonary disease. Shi Yong Zhong Yi
Yao Za Zhi 2012; 28(9): 802-803.
10 Li JS, Wang ZW, Yu XQ, Wang MH, Li SY. Clinical effi-
9
JTCM |www. journaltcm. com
LiuW et al. / Systematic Review
February 15, 2015 |Volume 35 | Issue 1 |
cacy and safety of TCM for chronic obstructive pulmo-
nary disease at stable phase: a systematic review. Liaoning
Zhong Yi Za Zhi 2010; 37(2): 229-232.
11 Guo R, Pittler MH, Ernst E. Herbal medicines for the
treatment of COPD: a systematic review. Eur Respir J
2006; 28(2): 330-338.
12 Zhang W, Shao YM, Zhang XY. Key points to the patho-
genesis of chronic obstructive pulmonary disease: phlegm,
stasis and deficiency. Zhong Guo Zu Zhi Gong Cheng
Yan Jiu Yu Lin Chuang Kang Fu 2007; 11(8): 187-189.
13 Zhang W, Li G, Zhang XY, Shao YM. Chronic obstruc-
tive disease of lung treated with phlegm, stasis and defi-
ciency according with different symptoms. Zhong Yi Yao
Xin Xi 2006; 23(5): 267-268.
14 Zhang DB. The understanding of the Traditional Chinese
Medicine for chronic obstructive pulmonary disease.
Zhong Guo Zhong Yi Ji Zheng 2009; 18(12): 1999-2000.
15 An X, Zhang AL, Yang AW, et al. Oral ginseng formulae
for stable chronic obstructive pulmonary disease: a system-
atic review. Respir Med 2011; 105(2): 165-176.
16 Wang B, Wu W, Wang W, Gao F. Clinical research of Tra-
ditional Chinese Medicine with tonifying-fei, resolving
phlegm and promoting blood stasis on chronic obstructive
pulmonary disease associated with pulmonary hyperten-
sion. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi 2012; 7
(19): 72-73.
17 Li D. Research of clinical application of Chinese patent
medicines in chronic obstructive pulmonary disease in re-
cent five years. Beijing: Beijing University of Traditional
Chinese Medicine, 2009: 71-111.
18 Zhen XY. Guiding principle of clinical research on new
drugs of Traditional Chinese Medicine (trial implementa-
tion). Beijing: Chinese Medical Science and Technology
Press, 2002: 54-58.
19 Bian ZX, Moher D, Li YP, et al. Appropriately selecting
and concisely reporting the outcome measures of random-
ized controlled trials of Traditional Chinese Medicine.
Zhong Xi Yi Jie He Xue Bao 2008; 6(8): 771-775.
20 Li SY, Li JS, Wang MH, et al. Effects of comprehensive
therapy based on Traditional Chinese Medicine patterns in
stable chronic obstructive pulmonary disease: a four-cen-
ter, open-label, randomized, controlled study. BMC Com-
plement Altern Med 2012; 12: 197.
21 Higgins JPT, Altman DG, Sterne JAC (editors) (2011)
Chapter 8: Assessing risk of bias in included studies. In:
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updat-
ed March 2011). The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
22 Review Manager (RevMan) [Computer program]. Version
5.2. Copenhagen: The Nordic Cochrane Centre, The Co-
chrane Collaboration, 2012.
23 Fu M. Clinical effect evaluation and mechanism discus-
sion of "Bufei granule" on patients with steady chronic ob-
structive pulmonary disease. TianJin: Tianjin University of
Traditional Chinese Medicine, 2012: 39-46.
24 Gao J, Gao FA. Clinical study on Gubenkechuan capsule
in the treatment of senile chronic bronchitis. Zhong Guo
Ji Ceng Yi Yao 1999; 6(3): 166-167.
25 Sun ZT, Liu ES, Feng JH, Fu M. Clinical effect research
of Bufei granule in patients with steady chronic obstruc-
tive pulmonary disease. Xin Zhong Yi 2009; 41(3): 37-38.
26 Zhou QW, Li SY, Wu JZ. The influence of Huanfei gran-
ules on pulmonary ventilation functions of patients in
steady chronic obstructive pulmonary disease. Zhong Guo
Zhong Xi Yi Jie He Za Zhi 2005; 25(7): 649.
27 Wu L, Lin L, Xu YJ, et al. Clinical research on 178 cases
of chronic obstructive pulmonary disease in the stable
stage treated with jianpi yifei Ⅱ. Zhong Yi Za Zhi 2011;
52(17): 1465-1468.
28 Zhong HW, Peng SL, Luo YB, Gao HY, Ao SH, Wang JF.
The clinical effect of Feishu capsule on steady stage of
COPD. Tianjin Yi Yao 2010; 38(10): 849-851.
29 Zhang W, BI XL, Bao BQ, Yu HM, Tao HM. Clinical re-
search on Fuzhenghuayu Capsule treating chronic obstruct
pulmonary. Liaoning Zhong Yi Za Zhi 2008; 36(8):
1174-1175.
30 Gong J. The Research on Efficacy of Chronic Obstructive
Pulmonary Disease with Deficiency of both Lung and
Spleen in Stable Condition with the Management of
Qiangjijianli OraI Liquid. Guangzhou: Guangzhou Uni-
versity of Traditional Chinese Medicine, 2007: 24-30.
31 Fang LP, Cong P, Feng L, Chen L. Clinical observation
on chronic obstructive pulmonary disease in stable stage
treated by principle of invigorating lung and kidney.
Henan Zhong Yi Za Zhi 2008; 28(7): 41-43.
32 Hong ML, Dai SZ, Lin XQ. The clinical effects of Yufein-
ing in patients with chronic obstructive pulmonary disease
at stable phase. Zhong Yi Yao Xue Kan 2005; 23(2):
297-298.
33 Zhu LF, Bian YJ, Zheng F, et al. Clinical Study on the Ef-
fects of Bufei Yishen Treatment on Quality of Life of Pa-
tients with Chronic Obstructive Pulmonary Disease in Sta-
ble Period. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi
2009; 16(12): 13-14.
34 Cai M, Chen H, Wang XD. Clinical observation of Bush-
en Naqi Huoxue Granules in treating patients with chron-
ic obstructive lung disease. Zhong Guo Zhong Xi Yi Jie
He Za Zhi 2005; 3(6): 483-485.
35 Wang YF. Clinical study of Bushen Yifei capsule in treat-
ment of chronic obstructive pulmonary disease. Shan
Dong Yi Yao 2007; 47(13): 30-31.
36 Group of Chronic Obstructive Pulmonary Diseases, Com-
mittee of Respiratory Disease, Chinese Medical Associa-
tion. Guideline for diagnosis and treatment of chronic ob-
structive pulmonary disease. Zhong Guo Jie He He Hu Xi
Za Zhi 2007; 30(1): 8-17.
37 Chen GT, Xue SQ. The latest disease diagnosis and treat-
ment standards at home and abroad. Beijing: the Academy
Press, 1992: 115.
38 Cai YY, Liang YJ, Wang ZX, Fang ZJ, Chen JR. Research
of lung function and quality of life of patients with chron-
ic obstructive pulmonary disease. Zhong Guo Kang Fu YI
Xue Za Zhi 1997; 12(6): 241-246.
39 Ernst E, Lee MS. A trial design that generates only posi-
tive results. J Postgrad Med 2008; 54(3): 214-216.
40 Liu WM, Liu BY, He LY, et al. Thinkings and practical
exploration for introducing GRADE to researching of
TCM and producing international standards for Tradi-
tional Chinese Medicine. Ya Tai Chuan Tong Yi Yao
2011; 1(7): 1-5.
10
